Efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a prospective cohort study with propensity-score matching.
[BACKGROUND] This study compared the efficacy of neoadjuvant immunochemotherapy (nICT) followed by surgery versus upfront surgery for locally advanced esophageal squamous cell carcinoma (ESCC).
- p-value p<0.001
- p-value p=0.002
- HR 0.31
APA
Zhang S, Hu A, et al. (2025). Efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a prospective cohort study with propensity-score matching.. Frontiers in immunology, 16, 1711095. https://doi.org/10.3389/fimmu.2025.1711095
MLA
Zhang S, et al.. "Efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a prospective cohort study with propensity-score matching.." Frontiers in immunology, vol. 16, 2025, pp. 1711095.
PMID
41567204
Abstract
[BACKGROUND] This study compared the efficacy of neoadjuvant immunochemotherapy (nICT) followed by surgery versus upfront surgery for locally advanced esophageal squamous cell carcinoma (ESCC).
[METHODS] In this prospective controlled trial (2020-2025), 623 stage II-IIIB ESCC patients were included; 192 received nICT (cisplatin, nab-paclitaxel, sintilimab) before surgery, and 431 underwent direct surgery. Propensity-score matching (PSM) and overlap weighting were used to adjust for baseline confounders.
[RESULTS] After PSM (144 pairs), the nICT group showed significantly improved progression-free survival (PFS; HR = 0.31, p<0.001) and overall survival (OS; HR = 0.42, p=0.002) compared to the upfront surgery group. The nICT group also had higher 1-/3-year PFS (88.8%/84.3% vs. 68.1%/52.8%) and OS rates (94.8%/84.7% vs. 89.6%/65.2%). Sensitivity analysis using overlap weighting confirmed these robust findings (PFS: HR = 0.37, p<0.001; OS: HR = 0.62, p=0.033).
[CONCLUSIONS] For locally advanced ESCC, neoadjuvant immunochemotherapy significantly improves both PFS and OS compared to upfront surgery, establishing it as a highly effective treatment strategy.
[METHODS] In this prospective controlled trial (2020-2025), 623 stage II-IIIB ESCC patients were included; 192 received nICT (cisplatin, nab-paclitaxel, sintilimab) before surgery, and 431 underwent direct surgery. Propensity-score matching (PSM) and overlap weighting were used to adjust for baseline confounders.
[RESULTS] After PSM (144 pairs), the nICT group showed significantly improved progression-free survival (PFS; HR = 0.31, p<0.001) and overall survival (OS; HR = 0.42, p=0.002) compared to the upfront surgery group. The nICT group also had higher 1-/3-year PFS (88.8%/84.3% vs. 68.1%/52.8%) and OS rates (94.8%/84.7% vs. 89.6%/65.2%). Sensitivity analysis using overlap weighting confirmed these robust findings (PFS: HR = 0.37, p<0.001; OS: HR = 0.62, p=0.033).
[CONCLUSIONS] For locally advanced ESCC, neoadjuvant immunochemotherapy significantly improves both PFS and OS compared to upfront surgery, establishing it as a highly effective treatment strategy.
MeSH Terms
Humans; Male; Esophageal Squamous Cell Carcinoma; Female; Neoadjuvant Therapy; Middle Aged; Esophageal Neoplasms; Propensity Score; Prospective Studies; Aged; Antineoplastic Combined Chemotherapy Protocols; Treatment Outcome; Paclitaxel; Neoplasm Staging; Adult; Cisplatin; Immunotherapy
같은 제1저자의 인용 많은 논문 (5)
- An Easy and Cost-Effective Method to Perform the "No-Touch" Technique in Saline Breast Augmentation.
- Establishing a knowledge-based planning model for left-sided breast cancer patients receiving hypofractionated postmastectomy and regional nodal irradiation.
- Copper-enriched zinc peroxides induced cuproptosis through concurrent metabolic and oxidative dysregulation for boosting immunotherapy in colorectal cancer.
- Identifying Low-Risk Patients with Cirrhosis and Acute Gastrointestinal Bleeding That May Not Require Urgent Endoscopy.
- Esophageal cancer: from pathogenesis to precision therapies.